Drug-Resistant Tuberculosis: Causes, Diagnosis and Treatments $129.00
Editors: Shui Ngụy and Zhou K'ung
Book Description:
Tuberculosis (TB) is a major public health problem of global proportions. It is the second leading cause of death from an infectious agent, killing nearly two million people each year, mostly in developing countries. This book outlines the recent advances in the development of new multidrug-resistant tuberculosis (MDR-TB) drugs. The emergence of resistance to antituberculosis drugs, particularly of MDR-TB and newly XDR-TB has become a major health problem. This book provides some glimpses into the current drugs including their mechanism of action, side-effects and mechanism of resistance. The desirable features of new drugs is also discussed, as well as different targets for effective TB treatment and approaches that are being made in the development of potential drugs for resistant tuberculosis. The effectiveness of levofloxacin and olfoxacin in the treatment of multi-drug resistant tuberculosis is also comparatively assessed to determine the immunological effects of certain treatment regimens. Finally, this book expands upon the spectrum of potential resistance-related mutations in MTB clinical isolates to help consolidate the framework for the development of molecular methods for delineating the drug susceptibility profiles in clinical laboratories.
Table of Contents:
Preface
Chapter I. Drug-Resistant Tuberculosis: Causes, Diagnosis and Treatment, pp. 1-58
(Suhail Ahmad, Eiman Mokaddas, Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait)
Chapter II. Tuberculosis – The Development of New MDR-TB Drugs , pp. 59-141
(Jarmila Vinšová, Martin Krátký, Faculty of Pharmacy, Charles University, Czech Republic)
Chapter III. Recent Advances towards the Development of New Drugs for Resistant Tuberculosis , pp. 143-176
(Ahmed Kamal, Shaik Azeeza, M. Shaheer Malik, Chemical Biology Laboratory, Division of Organic Chemistry, Indian Institute of Chemical Technology, India)
Chapter IV. Molecular Basis of Ethambutol Resistance in Mycobacterium Tuberculosis: Current Insights , pp. 177-200
(Igor Mokrousov, Laboratory of Molecular Microbiology, St. Petersburg Pasteur Institute, Russia)
Chapter V. Drug Resistant Tuberculosis in Bulgaria: Molecular Insights, pp. 201-223
(Violeta Valcheva, Nadya Markova, Nalin Rastogi, Olga Narvskaya, Igor Mokrousov, Department of Pathogenic Bacteria, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria, and others)
Chapter VI. Administration of TB Drugs in Resistance Cases Based on Bacterial Gene Expression Profiling , pp. 225-236
(Li M. Fu, Pacific Tuberculosis and Cancer Research Organization, Irvine, CA)
Chapter VII. A Prospective Assessment of Therapeutic Efficacy and Immune Effects of Levofloxacin and Ofloxacin in Multiple-Drug Resistant Tuberculosis, pp. 237-249
(Philip Martin Clark, Sule Apikoglu-Rabus, Bayram Kiran, Turan Karagoz, Fikret Vehbi Izzettin, Yeditepe University Department of Pharmacy, Istanbul, Turkey, and others)
Chapter VIII. Clinical and Pathomorphological Aspects of Tuberculosis in Hungary, pp. 251-262
(Losonczy György; Törõ Klára, Semmelweis University, Pulmonologal Clinic, Semmelweis University, Department of Forensic and Insurance Medicine)
Chapter IX. Management of Multi-Drug-Resistant Tuberculosis – Back to the Future? , pp. 263-273
(Wing-Wai Yew, Chen-Yuan Chiang, Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong, China, and others)
Chapter X. Genetic and Phenotypic Characterization of Drug-Resistant Mycobacterium Tuberculosis Isolates , pp. 275-285
(Maysaa El Sayed Zaki, Professor of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt)
Chapter XI. Tuberculosis Treatment Failure: Causes and Solutions, pp. 287-307
(Philip Martin Clark, Sule Apikoglu-Rabus, Yeditepe University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey and others)
https://www.novapublishers.com/catalog/product_info.php?products_id=24082&osCsid=
Editors: Shui Ngụy and Zhou K'ung
Book Description:
Tuberculosis (TB) is a major public health problem of global proportions. It is the second leading cause of death from an infectious agent, killing nearly two million people each year, mostly in developing countries. This book outlines the recent advances in the development of new multidrug-resistant tuberculosis (MDR-TB) drugs. The emergence of resistance to antituberculosis drugs, particularly of MDR-TB and newly XDR-TB has become a major health problem. This book provides some glimpses into the current drugs including their mechanism of action, side-effects and mechanism of resistance. The desirable features of new drugs is also discussed, as well as different targets for effective TB treatment and approaches that are being made in the development of potential drugs for resistant tuberculosis. The effectiveness of levofloxacin and olfoxacin in the treatment of multi-drug resistant tuberculosis is also comparatively assessed to determine the immunological effects of certain treatment regimens. Finally, this book expands upon the spectrum of potential resistance-related mutations in MTB clinical isolates to help consolidate the framework for the development of molecular methods for delineating the drug susceptibility profiles in clinical laboratories.
Table of Contents:
Preface
Chapter I. Drug-Resistant Tuberculosis: Causes, Diagnosis and Treatment, pp. 1-58
(Suhail Ahmad, Eiman Mokaddas, Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait)
Chapter II. Tuberculosis – The Development of New MDR-TB Drugs , pp. 59-141
(Jarmila Vinšová, Martin Krátký, Faculty of Pharmacy, Charles University, Czech Republic)
Chapter III. Recent Advances towards the Development of New Drugs for Resistant Tuberculosis , pp. 143-176
(Ahmed Kamal, Shaik Azeeza, M. Shaheer Malik, Chemical Biology Laboratory, Division of Organic Chemistry, Indian Institute of Chemical Technology, India)
Chapter IV. Molecular Basis of Ethambutol Resistance in Mycobacterium Tuberculosis: Current Insights , pp. 177-200
(Igor Mokrousov, Laboratory of Molecular Microbiology, St. Petersburg Pasteur Institute, Russia)
Chapter V. Drug Resistant Tuberculosis in Bulgaria: Molecular Insights, pp. 201-223
(Violeta Valcheva, Nadya Markova, Nalin Rastogi, Olga Narvskaya, Igor Mokrousov, Department of Pathogenic Bacteria, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria, and others)
Chapter VI. Administration of TB Drugs in Resistance Cases Based on Bacterial Gene Expression Profiling , pp. 225-236
(Li M. Fu, Pacific Tuberculosis and Cancer Research Organization, Irvine, CA)
Chapter VII. A Prospective Assessment of Therapeutic Efficacy and Immune Effects of Levofloxacin and Ofloxacin in Multiple-Drug Resistant Tuberculosis, pp. 237-249
(Philip Martin Clark, Sule Apikoglu-Rabus, Bayram Kiran, Turan Karagoz, Fikret Vehbi Izzettin, Yeditepe University Department of Pharmacy, Istanbul, Turkey, and others)
Chapter VIII. Clinical and Pathomorphological Aspects of Tuberculosis in Hungary, pp. 251-262
(Losonczy György; Törõ Klára, Semmelweis University, Pulmonologal Clinic, Semmelweis University, Department of Forensic and Insurance Medicine)
Chapter IX. Management of Multi-Drug-Resistant Tuberculosis – Back to the Future? , pp. 263-273
(Wing-Wai Yew, Chen-Yuan Chiang, Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong, China, and others)
Chapter X. Genetic and Phenotypic Characterization of Drug-Resistant Mycobacterium Tuberculosis Isolates , pp. 275-285
(Maysaa El Sayed Zaki, Professor of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt)
Chapter XI. Tuberculosis Treatment Failure: Causes and Solutions, pp. 287-307
(Philip Martin Clark, Sule Apikoglu-Rabus, Yeditepe University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey and others)
https://www.novapublishers.com/catalog/product_info.php?products_id=24082&osCsid=
No comments:
Post a Comment